BAX and B-cell chronic lymphocytic leukemia: In contrast, ibrutinib treatment of the CLL cybrid caused a significant decrease in the relative fold change of BAX (fold change = −0.4, p < 0.0001) and CASP3 (fold change = −0.5, p < 0.01) expression (Figure 4).